BioNTech (NASDAQ:BNTX) PT Raised to $113.00 at HC Wainwright

BioNTech (NASDAQ:BNTX - Free Report) had its target price upped by HC Wainwright from $107.00 to $113.00 in a research note published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $99.00 to $90.00 and set an underweight rating on the stock in a research report on Friday, March 22nd. UBS Group reduced their price objective on shares of BioNTech from $110.00 to $101.00 and set a neutral rating on the stock in a research note on Wednesday, March 27th. TD Cowen upped their target price on shares of BioNTech from $95.00 to $98.00 and gave the company a hold rating in a research report on Tuesday. BMO Capital Markets reduced their price target on BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research report on Tuesday. Finally, The Goldman Sachs Group cut their target price on BioNTech from $113.00 to $100.00 and set a neutral rating on the stock in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of Hold and a consensus target price of $118.82.

BioNTech Stock Performance

Shares of BNTX stock traded down $0.75 during trading on Wednesday, reaching $90.13. The company had a trading volume of 343,955 shares, compared to its average volume of 654,084. BioNTech has a one year low of $85.21 and a one year high of $125.83. The company has a market capitalization of $21.43 billion, a PE ratio of 22.06 and a beta of 0.25. The firm's 50 day simple moving average is $90.50 and its two-hundred day simple moving average is $95.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. Sell-side analysts forecast that BioNTech will post -1.74 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Baillie Gifford & Co. lifted its holdings in shares of BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company's stock valued at $917,056,000 after purchasing an additional 86,343 shares in the last quarter. Primecap Management Co. CA increased its stake in BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company's stock valued at $502,735,000 after buying an additional 131,490 shares during the last quarter. Harding Loevner LP bought a new stake in BioNTech during the 4th quarter worth about $410,984,000. Flossbach Von Storch AG boosted its position in BioNTech by 1.0% during the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company's stock valued at $374,526,000 after purchasing an additional 35,445 shares during the last quarter. Finally, Capital World Investors grew its stake in BioNTech by 1.5% in the fourth quarter. Capital World Investors now owns 938,747 shares of the company's stock valued at $99,075,000 after purchasing an additional 14,027 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.